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MINIATURE AXIAL FLOW 
PUMP FOR VENTRICULAR 
ASSISTANCE IN CHILDREN 
AND SMALI. ADULTS 
We investigated the eflicacy of the Jarvik 2000 intraventricular assist device 
(Jarvik Research, Inc., New York, N.Y.) in an ovine model. The device is an 
axial flow pump measuring 1.8 cm in diameter by 5 cm long, has a 
displacement volume of 12 ml, and can deliver flow from 2 to 7 L/min. Seven 
devices were implanted through a ler thoracotomy into the left ventricle 
with an outflow graft to the descending aorta. Animals were treated with 
warfarin sodium and aspirin to maintain prothrombin times approximately 
1.5 times control. Animals were followed up for 3 to 123 days. Two animals 
died of operative complications at days 3 and 5. One device failed at 58 days 
because of thrombus formation at the inflow side of the impeller. The 
remaining four animals were killed at days 19, 42, 42, and 123, respectively, 
because of broken electric power cables. Hematocrit values rose signifi- 
cantly higher than preoperative levels (22.8% +- 3.8% to 30.5% -+ 3.4%); 
premortem elevations of values higher than baseline values of plasma free 
hemoglobin (10.4 -+ 7.8 mg/dl to 17.1 - 7.4 mg/dl) and lactate dehydroge- 
nase (391.5 --- 113.7 units/L to 771.2 "4- 370.8 units/L) were statistically 
insignificant. Serum creatinine and bilirubin levels were normal. No 
end-organ dysfunction arising from Iong-term support was evident clini- 
cally or at postmortem examination, nor was there any evidence of 
embolism or damage to intracardiac structures. We found the Jarvik 2000 
intraventricular assist device to be easily implantable, safe, nonhemolytic, 
and able to provide physiologic flow with power requirements under 10 
watts. (J THORAC CARDIOVASC SURG 1996;111:13-8) 
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W ith approximate 1-and 5-year survivals of 80% and 60%, respectively, cardiac transplantation 
has become accepted as the treatment of choice for 
patients with end-stage heart failure. 1 Unfortu- 
nately, the critical shortage of available donor or- 
gans is the foremost limitation to heart transplanta- 
tion and is such that the number of patients on the 
United Network for Organ Sharing (UNOS) waiting 
list exceeds the number of patients who undergo 
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transplantation annually almost fourfold. 2 Despite 
continually expanding donor criteria, many patients 
who might benefit from cardiac transplantation are 
considered too old or too sick to be offered this 
therapeutic modality and as many as 20% die while 
awaiting an organ)' 4 
Since Reemtsma and colleagues s first demon- 
strated that "bridging" to heart transplantation with 
mechanical assistance could be successfully done, 
left ventricular assist devices (LVADs) have become 
more widely used. 6' 7 Unfortunately, placement of 
the two devices specifically designed for long-term 
mechanical circulatory support, the HeartMate 1000 
IP device (Thermocardiosystems Inc., Woburn, 
Mass.) and the Novacor LVAS (Novacor Medical 
Corp., Oakland, Calif.), has been technically unfea- 
sible in patients with body surface areas less than 
1.5 m a, thus excluding small women and children, s 
In contrast to pusher-plate devices, axial flow 
pumps are small. Further, such devices are quiet, 
easily implantable, and relatively inexpensive. 9 To 
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Fig. 1. Jarvik 2000 intraventricular xial flow assist device measures 1.8 cm in diameter by 5 cm in length 
and has displacement volume of 12 ml. Rotor is encased in titanium shell and is supported at each end by 
tiny blood-immersed ceramic bearing 1 mm in diameter. 
date, however, exper imental  and clinical trials with 
axial flow pumps have demonstrated l imited flows, 
hemolysis, p latelet  destruction, thrombus format ion 
on impel ler  blades, device overheating, and l imited 
durat ion of implantat ion. 9-14 
In response to the need for a ventr icular assist 
device for smaller patients, we evaluated a novel 
axial flow intraventr icular device, the Jarvik 2000 
pump (Jarvik Research,  Inc., New York, N.Y.), in 
an ovine model.  Parameters  addressed included 
safety, durabil ity, hemolysis, thromboembol ism,  and 
power requirement.  
Material and methods 
Device. The Jarvik 2000 device is an intraventricular 
axial flow impeller pump that measures 1.8 cm in diameter 
by 5 cm in length, weighs 45 gin, and has a displacement 
volume of 12 Inl (Fig. 1). In vitro studies with this device 
have demonstrated flow rates from 2 to 7 L/min in a 
water-glycerol test solution with viseosity similar to that of 
blood at 100 mm differential pressure. Normal operating 
speeds of 16,000 to 18,000 rpm produce flow rates from 3 
to 6 L/min at 80 mm Hg mean aortie pressure (Fig. 2). 
Power to the device is provided by a direct current power 
supply and regulated by a pulse width-modulated brush- 
less direct current motor controller to set motor speed. 
The deviee is placed into the apex of the left ventricle 
with outflow via a 12 mm Dacron graft to the descending 
thoracic aorta. Several stator blade and rotor configura- 
tions were tested in vitro and in vivo to minimize bearing 
wear, hemolysis, and power requirement. 
Animals. In vivo studies with the Jarvik 2000 axial flow 
pump were conducted in mature sheep (n = 7) weighing 
55.1 +_ 10.3 kg. Surgical procedures and subsequent eare 
of animals were done in eompliance with the "Prineiples 
of Laboratory Animal Care" formulated by the National 
Society for Medical Research and the "Guide for the Care 
and Use of Laboratory Animals" prepared by the Na- 
tional Academy of Sciences and published by the National 
Institutes of Health (NIH Publication No. 85-23, revised 
1985). 
Operative procedure. Animals were sedated with ket- 
amine hydrochloride (10 mg/kg intramuscularly) and at- 
ropine sulfate (0.4 mg/kg intramuscularly), anesthetized 
with inhalational isoflurane (0.5 minimal alveolar concen- 
tration) and the lungs ventilated through an endotraeheal 
tube with an inspired oxygen fraction of 100%. Animals 
were monitored continuously for arterial blood pressure 
and electrocardiogram. 
Device placement was done initially with the use of 
cardiopulmonary b pass (n = 4); however, we found this 
to be unnecessary and the remaining animals were oper- 
ated on without cardiopulmonary b pass (n = 3). After 
standard left thoracotomy, the animals were fully antico- 
agulated with heparin and the 12 mm Dacron outflow 
graft was preclotted with nonheparinized autologous 
blood. The descending thoracic aorta was partially oc- 
cluded with a vascular clamp and the Dacron graft anas- 
tomosed to the aorta in an end-to-side manner. 
The power cable was tunneled through the soft tissues 
and exteriorized on the left flank. In animals undergoing 
cardiopulmonary bypass, cannulas were placed in the 
external jugular vein and the ascending aorta or Dacron 
graft and bypass was initiated; in the remaining animals, 
lidocaine 100 mg was injected into the pericardium to 
avoid ventricular arrhythmias during manipulation of the 
heart. 
A silicone-reinforced Dacron velour sewing ring was 
attached to the apex of the left ventricle with braided 
polyester sutures supported with felt pledgets. An exci- 
sional apical left ventriculotomy through the sewing ring 
was created with a cylindrical coring knife through which 
the device was inserted. Bleeding from the apex was 
controlled by manual compression of the heart during 
device insertion. The device was secured to the sewing 
ring with umbilical tape purse-string ties. The outflow 
graft was vented to remove residual air and pumping was 
initiated. An ultrasonic flow probe (Transonic Systems, 
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Fig. 2. In vitro studies with Jarvik 2000 intraventricular 
assist device have demonstrated flow rates from 2 to 7 
L/min in water.-glycerol test solution with viscosity similar 
to that of blood. At normal operating speeds of 16,000 to 
18,000 rpm, device produces flow rates from 3 to 6 L/min 
at 80 mm Hg mean aortic pressure. AoP, Aortic pressure; 
LVP, left ventricular pressure. 
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Fig. 3. Before placement of Jarvik 2000 intraventricular 
assist device, sheep were anemic with mean hematocrit 
(HcO of 22.8% _+ 3.8% (n = 7). During course of 
mechanical support, mean hematocrit values rose signifi- 
cantly to 30.5% -+ 3.4% (p = 0.01). 
Inc., Ithaca, N.Y.; n = 3) was placed around the graft, flow 
recorded, and the flow probe removed. A chest ube was 
placed for drainage, the incisions closed, and the animals 
returned to their cages. 
Postoperatiw~ care and monitoring. Chest tubes were 
removed within 24 hours of operation. Heparin 1000 
units per hour was started on the morning after the 
operation and continued for 3 days. Aspirin 325 mg and 
warfarin sodium were given daily starting on the morn- 
ing after the operation; warfarin sodium was dosed to 
maintain prothrombin times approximately 1.5 times 
the control value. Device motor speed, voltage, and 
current were monitored continuously. Serum samples 
were collecied serially to determine blood cell counts, 
blood chemistry values, prothrombin times, and levels 
of plasma free hemoglobin. 
Results  
The animals urvived from 3 to 123 days. The first 
two animals died as a result of technical complica- 
tions on days 3 and 5, respectively. In the first sheep, 
the device was oriented with the inflow stator di- 
rected toward the interventricular septum. Septal 
compression led to infarction with subsequent right 
ventricular :failure and death. The second animal 
died as a resuh: of hemorrhage from the anastomosis 
of the Dacron graft and aorta. 
The remaining animals survived 57 + 18 days. Of 
these, the first animal was killed on postoperative 
day 42 when the power cable to the device broke at 
the point of insertion into the pump, likely as a 
result of animal growth during the course of me- 
chanical support and mechanical stress caused by 
movement. Similarly, the next animal was killed 
because of a broken power cable on postoperative 
day 19. This break occurred as a result of the cable 
having been brought out too low along the flank, 
which allowed the sheep to lie on the cord. A third 
animal was killed on postoperative day 58 when 
device function became erratic, which necessitated 
the use of increased power to maintain motor speed. 
Postmortem examination of this device demon- 
strated a small ring of thrombus at the inflow stator, 
presumably caused by turbulent flow at that point. 
The impeller blades were modified to further mini- 
reize flow turbulence and the next two animals did 
well until they were killed on days 123 and 42 
because of broken power cables, again as a result of 
animal movement and growth during the course of 
mechanical support. 
In all animals, a small ring of thrombus approxi- 
mately 1 mm thick was present at the bearing that 
supported each end of the rotor. In the animal that 
survived 123 days, a thin capsule formed over the 
surface of the rotor hub but did not cover the 
impeller blades. None of the animals evidenced 
end-organ dysfunction clinically, and at autopsy no 
emboli were found in peripheral arteries. Two of the 
animals had mild, local skin infections at the power 
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Fig. 4. Except for early perioperative thrombocytosis, 
platelet counts were normal in all sheep (n = 7). None of 
sheep had thrombocytopenia at ny time while supported 
by Jarvik 2000 intraventricular ssist device. 
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Fig. 5. Mean bilirubin and creatinine levels were within 
normal limits for all sheep (n = 7) during mechanical 
support. 
cable egress ite; however, these were easily treated 
with dressing changes. 
The sheep were anemic before device implantation; 
however, during the time that the animals were as- 
sisted by the device, mean hematocrit values rose 
significantly ffom 22.8% +_ 3.8% before operation to 
30.5% +_ 3.4% (p = 0.01) before they were killed (Fig. 
3). After an early thrombocytosis, platelet counts re- 
turned to normal (Fig. 4) and the animals were never 
thrombocytopenic. Bilirubin and creatinine levels re- 
mained within the control range (Fig. 5). Elevations 
higher than baseline levels of mean plasma free hemo- 
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Fig. 6. Mean plasma free hemoglobin (Hgb) levels were 
insignificantly (p -- 0.1) elevated in comparison with 
baseline levels for all sheep (n = 7) mechanically sup- 
ported by Jarvik 2000 intraventricular ssist device. 
globin from 10.4 _+ 7.8 mg/dl to 17.1 _+ 7.4 mg/dl 
before the animals were killed were statistically insig- 
nificant (p = 0.1, Fig. 6) as were elevations in mean 
lactate dehydrogenase l vels from 391.5 _+ 113.7 
units/L to 771.2 +_ 370.8 units/L (p = 0.1, Fig. 7). 
Flow through the Dacron graft, as measured intra- 
operatively with ultrasonic flow probes, validated the 
flow rates demonstrated in vitro (Fig. 8). In that 
preload to the device varied with native heart contrac- 
tion, outflow from the device was pulsatile in nature. 
At higher speeds with the ventricle fully unloaded, 
however, flow from the device became nonpulsatile. 
When the device was momentarily turned oft, flow 
through the Dacron graft was reversed. This functional 
"aortic insufficiency" was tolerated by the animals. 
Discussion 
The principle of operation of the Jarvik 2000 
intraventricular assist device is extremely simple. 
The rotor of a brushless direct-current motor, a 
small high-strength magnet about 5 mm in diameter 
by 2 cm long, is encased in a titanium shell that 
supports the blades of a miniature axial flow pump. 
This constitutes the sole moving part of the device 
and is supported at each end by a tiny blood- 
immersed ceramic bearing 1 mm in diameter. Be- 
cause the bearings are so small, the surface rubbing 
speed even at 20,000 rpm is very low and there is 
virtually no wear. The rotor is supported for rotation 
within the bore of the motor stator, which is also 
encased by titanium, and the forces to spin the rotor 
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Fig. 7. Mean lactate dehydrogenase (LDH) levels were 
insignificantly (p = 0.1) elevated in comparison with 
baseline levels in those sheep tested while mechanically 
supported by Jarvik 2000 intraventricular assist device. 
are transmitted magnetically across the blood flow- 
ing through the bore of the motor. A small ring of 
thrombus is permitted to form immediately at the 
bearing sites, but this is in the form of a tiny torus 
that cannot break free and embolize because it is 
retained by the bearing shaft that passes through 
the center. A critical feature of the design is that 
a high-flow stream of blood passes across each 
bearing to prevent he thrombus from becoming 
much larger than the tiny gap it fills. One of the 
major objectives of this study was to establish that 
the flow in vivo was sufficient o properly wash the 
bearings. 
In these animal experiments, we found the Jarvik 
2000 intraventricular ssist device to be entirely free 
from embolic complications, easy to manage in the 
long term, and able to deliver up to 5 L per minute 
of flow in seven sheep. Further, unlike currently 
i 
available pusher-plate type LVADs, the Jarvik 2000 
device is small enough to be implanted into patients 
with body surface areas less than 1.5 m e. 
After inilial experiments during which we learned 
how best te place this device in the heart, survival of 
the sheep was limited primarily by the animals' 
either chewing or breaking the power cables. Fur- 
ther devm e development with improved stress relief 
of the wirts is under way. The device in the fifth 
animal likely failed because of a small ring of 
thrombus at the inflow stator, and after impeller 
blade modification o evidence of thrombus forma- 
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Fig. 8. Flow and pressure tracings recorded with Jarvik 
2000 intraventricular ssist device turned on and oft 
showed that flow from device, in this model, was pulsatile 
in nature. This was probably function of varied preload to 
device resulting from contractility of normal native heart; 
at higher pump speeds, flow from device became nonpul- 
satile. When device was turned oft, flow through Dacron 
graft was reversed as indicated by negative flow in flow 
tracing. This retrograde flow was tolerated by all animals. 
tion was noted in subsequent animals except hat of 
a small stable ring at the bearings. 
The slight elevations of levels of plasma free 
hemoglobin and serum lactate dehydrogenase ug- 
gest that some hemolysis occurred. However, stable 
postoperative hematocrit values indicate that this 
small degree of hemolysis was not clinically signifi- 
cant. 
None of the devices evidenced overheating or 
significant bearing wear. The minimal power re- 
quirements of the device (<10 watts) would permit 
long-term use with battery power supply. 
The arterial pressure tracings and flow probe 
recordings (Fig. 7) demonstrated that, in this model, 
flow from the device was pulsatile in nature. The 
pulse pressure recorded here was approximately 10 
mm Hg and although in the normal heart setting this 
is likely a result of residual myocardial function 
varying blood return to the device, at higher speeds 
with the ventricle completely unloaded we would 
expect a more continuous flow pattern. Nonetheless, 
pulsatile flow could be easily provided by cycling 
motor speed. 
Flow through the graft with the device turned oft 
was reversed, as indicated by the negative flow in the 
ftow probe tracing (Fig. 7). Because there is no valve 
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in the Dacron graft, when the ventricle ejects nor- 
mally through the aortic valve, retrograde flow 
through the graft occurs. Although this functional 
"aortic insufficiency" was well tolerated by all oB the 
animals, pump failure in the setting of heart failure 
would likely require immediate attention. 
Whereas the goal of this initial investigation of 
the Jarvik 2000 intraventricular support device was 
to address afety, durability, hemolysis, thromboem- 
bolism, and power requirements, future studies to 
determine the utility of this novel axial ftow intra- 
ventricular device should include investigations of 
longer-term animal survival and function in a small- 
er-animal, heart-failure model. We believe that the 
combination of ease of use, durability, and biocom- 
patibility in smaller patients will make this pump a 
suitable assist device for patients unable to tolerate 
the currently available larger LVADs. 
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